Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Case Reports
. 2022 Jul 18:12:867301.
doi: 10.3389/fonc.2022.867301. eCollection 2022.

Case Report: Invasive Fungal Infection and Daratumumab: A Case Series and Review of Literature

Francesca Farina  1 , V Ferla  1 , S Marktel  1 , D Clerici  1 , S Mastaglio  1 , T Perini  1   2 , C Oltolini  3 , R Greco  1 , F Aletti  1 , A Assanelli  1 , M T Lupo-Stanghellini  1 , M Bernardi  1 , C Corti  1 , F Ciceri  1   2 , M Marcatti  1
Affiliations
Case Reports

Case Report: Invasive Fungal Infection and Daratumumab: A Case Series and Review of Literature

Francesca Farina et al. Front Oncol. .

Abstract

Life expectancy of multiple myeloma (MM) patients has improved in last years due to the advent of anti-CD38 monoclonal antibodies in combination with immunomodulators and proteasome inhibitors. However, morbidity and mortality related to infections remain high and represent a major concern. This paper describes the "real life" risk of invasive fungal infections (IFI) in patients treated with daratumumab-based therapy and reviews the relevant literature. In a series of 75 patients we only observed three cases of fungal pneumonia. Unfortunately, the early signs and symptoms were not specific for fungal infection. Diagnostic imaging, microbiology and patient history, especially previous therapies, are critical in the decision to start antifungal treatment. Recognising the subgroup of MM patients with high risk of IFI can increase the rate of diagnosis, adequate treatment and MM-treatment recovery.

Keywords: complications; daratumumab; fungal infection; mould; multiple myeloma.

PubMed Disclaimer

Conflict of interest statement

The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.

Figures

Figure 1
Figure 1
Patient 1# CT scan.
Figure 2
Figure 2
Patient 2# CT scan.
Figure 3
Figure 3
Patient 3# CT scan.
See this image and copyright information in PMC

References

    1. Nucci M, Anaissie E. Infections in Patients With Multiple Myeloma in the Era of High-Dose Therapy and Novel Agents. Clin Infect Dis (2009) 49(8):1211. doi: 10.1086/605664 - DOI - PubMed
    1. Schütt P, Brandhorst D, Stellberg W, Poser M, Ebeling P, Müller S, et al. . Immune Parameters in Multiple Myeloma Patients: Influence of Treatment and Correlation With Opportunistic Infections. Leuk Lymphoma (2006) 47(8):1570. doi: 10.1080/10428190500472503 - DOI - PubMed
    1. De Pauw B, Walsh TJ, Donnelly JP, Stevens DA, Edwards JE, Calandra T, et al. . Revised Definitions of Invasive Fungal Disease From the European Organization for Research and Treatment of Cancer/Invasive Fungal Infections Cooperative Group and the National Institute of Allergy and Infectious Diseases Mycoses Study Group (EORTC/MSG) Consensus Group. Clin Infect Dis (2008) 46(12):1813–21. doi: 10.1086/588660 - DOI - PMC - PubMed
    1. Donnelly JP, Chen SC, Kauffman CA, Steinbach WJ, Baddley JW, Verweij PE, et al. . Revision and Update of the Consensus Definitions of Invasive Fungal Disease From the European Organization for Research and Treatment of Cancer and the Mycoses Study Group Education and Research Consortium. Clin Infect Dis (2020) 71(6):1367–76. doi: 10.1093/cid/ciz1008 - DOI - PMC - PubMed
    1. Available at: https://www.ema.europa.eu/en/documents/product-information/darzalex-epar....

Publication types